Efficacy and Safety of Yokukansan in Autism Spectrum disorder: A Randomized, Multi-center, Double-Blind, Placebo-Controlled Trial

Efficacy and Safety of Yokukansan in Autism Spectrum disorder: A Randomized, Multi-center, Double-Blind, Placebo-Controlled Trial - Efficacy and safety of yokukansan in autism spectrum disorder

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015708

Enrollment

100

Registered

2014-11-17

Start date

2015-01-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder

Interventions

Intervention: Yokukansan Control: Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: DSM-V: Autism Spectrum Disorder ABC-I: > 18 CGI-S: > 4

Exclusion criteria

Exclusion criteria: Presence of any active medical condition, diagnosis of any other psychiatric disorder on the DSM-5, use of any psychotropic medication in the six weeks prior to the baseline visit and history of hepatic disease or seizure could exclude the subject from this study.

Design outcomes

Primary

Measure	Time frame
Aberrant behavior checklist	—

Countries

Japan

Contacts

Public ContactSeiko Yano

Shimane University School of Medicine Psychiatry

book47@med.shimane-u.ac.jp0853-20-2262

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026